Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 3/20 | 0.67 |
| ▸ | SERPINC1 known ✓ | P01008 | 2/20 | 0.43 |
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.40 |
| ▸ | BDNF | P23560 | 3/20 | 0.52 |
| ▸ | MDK | P21741 | 3/20 | 0.52 |
| ▸ | PTN | P21246 | 2/20 | 0.52 |
| ▸ | BMP2 | P12643 | 3/20 | 0.47 |
| ▸ | VEGFA | P15692 | 3/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.47 |
| ▸ | SHH | Q15465 | 2/20 | 0.47 |
| ▸ | IFNG | P01579 | 2/20 | 0.45 |
| ▸ | PF4 | P02776 | 1/20 | 0.45 |
| ▸ | CCL2 | P13500 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | BMP6 | P22004 | 1/20 | 0.45 |
| ▸ | CCL11 | P51671 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | FGF2 | P09038 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28167126 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL28227554 | 0.99 | F10 (0.68) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL543122 | 0.99 | F10 (0.68) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL11557 | 0.99 | F10 (0.68) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL28297524 | 0.98 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Potassium Ion SCHEMBL28270668 | 0.98 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL28294039 | 0.98 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydroxyamine SCHEMBL28122321 | 0.98 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydrochloric Acid SCHEMBL28233049 | 0.98 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydrochloric Acid SCHEMBL28179031 | 0.98 | F10 (0.66) | F10BDNFMDKPTNBMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319138-A1 | METHOD FOR XENO-FREE GENERATION OF A POPULATION OF HMPC | Universitat Zürich (CH) | 2025-10-16 | — | — | US | disclosed |
| EP-4627056-A1 | METHOD OF PREPARING A MASS CULTURE OF MUSCLE PRECURSOR CELLS (MPCS) AND USES THEREOF | Universität Zürich (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-12370221-B2 | Method for xeno-free generation of a population of hMPC | Universität Zürich (CH) | 2025-07-29 | — | — | US | disclosed |
| CN-119015212-A | Levamisole nanostructure lipid carrier gel for treating allergic rhinitis | 福州辰星药业有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-221452304-U | A even agitating unit for heparin cream processing | 潢川县鹏升畜产品有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-12036234-B2 | Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues | NORTHWESTERN UNIVERSITY (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024115761-A1 | METHOD OF PREPARING A MASS CULTURE OF MUSCLE PRECURSOR CELLS (MPCS) AND USES THEREOF | Universität Zürich (CH) | 2024-06-06 | — | — | WO | disclosed |
| CN-117264892-B | In vitro preparation method of medial ganglion bulge progenitor cells and GABA (gamma-amino acid-gamma-amino acid) interneurons | 夏同生物科技(苏州)有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117264892-A | In vitro preparation method of medial ganglion bulge progenitor cells and GABA (gamma-amino acid-gamma-amino acid) interneurons | 夏同生物科技(苏州)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116650643-A | Bacterial biofilm microenvironment responsive gold nanoparticle, preparation and application | 华中科技大学 | 2023-08-29 | — | — | CN | disclosed |
| US-20230256022-A1 | C-KIT-POSITIVE BONE MARROW CELLS AND USES THEREOF | AAL SCIENTIFICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023083950-A1 | PARAPOXVIRUS FOR PREPARING FOR AND TREATMENT OF RESPIRATORY VIRUS INFECTIONS IN COMBINATION WITH IMMUNOMODULATORS | AICURIS GMBH & CO. KG (DE) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083943-A1 | PARAPOXVIRUS FOR PREPARING FOR AND TREATMENT OF RESPIRATORY VIRUS INFECTIONS IN COMBINATION WITH ANTIVIRALS | AICURIS GMBH & CO. KG (DE) | 2023-05-19 | — | — | WO | disclosed |
| EP-4146262-A1 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | AiCuris GmbH & Co. KG (DE) | 2023-03-15 | — | — | EP | disclosed |
| EP-3013463-B1 | CERAMIC WHOLE BLOOD HOLLOW FIBER MEMBRANE FILTER MEDIUM AND USE THEREOF FOR SEPARATING BLOOD PLASMA / SERUM FROM WHOLE BLOOD | MANN & HUMMEL GMBH (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-11547641-B2 | Sprayable high viscosity cosmetic formulation | BEIERSDORF AG (DE) | 2023-01-10 | — | — | US | disclosed |
| US-20220401553-A1 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO. KG (DE) | 2022-12-22 | — | — | US | disclosed |
| EP-3906970-B1 | PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO KG (DE) | 2022-07-06 | — | — | EP | disclosed |
| EP-3602070-B1 | A RAPID, ON-DEMAND HEPARIN-INDUCED THROMBOCYTOPENIA FUNCTIONAL ASSAY | EMOSIS (FR) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036234-B2 | Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues | COL14A1, MATR3, COL2A1 | F10 209/4885SERPINC1 5/4885FGF1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.